Orchard Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	0.88	1.55	2.21	4.25	7.96
Cash & Short-Term Investments	0.88	1.55	2.21	4.25	7.96
Cash Growth	-42.86%	-29.87%	-48.12%	-46.55%	-
Other Receivables	0.01	0.02	0.24	0.18	0.02
Receivables	0.01	0.02	0.24	0.18	0.02
Total Current Assets	0.9	1.57	2.44	4.43	7.97
Long-Term Investments	6.75	6.69	7.58	6.63	3.75
Total Assets	7.65	8.25	10.02	11.06	11.73
Accrued Expenses	0.11	0.14	0.14	0.18	0.11
Total Current Liabilities	0.11	0.14	0.14	0.18	0.11
Total Liabilities	0.11	0.14	0.14	0.18	0.11
Common Stock	11.65	11.65	11.65	11.65	11.52
Retained Earnings	-4.15	-3.58	-1.81	-0.8	-0.03
Comprehensive Income & Other	0.04	0.04	0.04	0.04	0.13
Shareholders' Equity	7.54	8.11	9.88	10.89	11.62
Total Liabilities & Equity	7.65	8.25	10.02	11.06	11.73
Net Cash (Debt)	0.88	1.55	2.21	4.25	7.96
Net Cash Growth	-42.86%	-29.87%	-48.12%	-46.55%	-
Net Cash Per Share	0.22	0.38	0.55	1.05	-
Filing Date Shares Outstanding	4.04	4.04	4.04	4.04	4.04
Total Common Shares Outstanding	4.04	4.04	4.04	4.04	4.04
Working Capital	0.78	1.42	2.3	4.26	7.86
Book Value Per Share	1.87	2.01	2.45	2.70	2.88
Tangible Book Value	7.54	8.11	9.88	10.89	11.62
Tangible Book Value Per Share	1.87	2.01	2.45	2.70	2.88

Source: S&P Global Market Intelligence. Standard template. Financial Sources.